[Malignant arterial hypertension. Intensive treatment by acute sodium depletion and antihypertensive agents].
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001835:Body Weight; D003404:Creatinine / Q000097:blood; D004039:Diet, Sodium-Restricted; D004232:Diuretics / Q000627:therapeutic use*; D005260:Female; D005654:Fundus Oculi; D005665:Furosemide / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications; D006334:Heart Function Tests; D006801:Humans; D006974:Hypertension, Malignant / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000150:complications; D007677:Kidney Function Tests; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D010530:Peritoneal Dialysis; D013148:Spironolactone / Q000627:therapeutic use; D014511:Uremia / Q000150:complications
D000959:Antihypertensive Agents; D004232:Diuretics; D013148:Spironolactone; D008750:Methyldopa; D005665:Furosemide; D003404:Creatinine
L'hypertension artérielle maligne. Traitement d'attaque par la déplétion sodée aiguë et les anti-hypertenseurs.